{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:43:56Z","timestamp":1792532636838,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The approved dose of nivolumab is 3\u2009mg\/kg or a flat dose of 240\u2009mg for indications. There is no dose-response relationship for nivolumab; therefore, a low-dose regimen may be an option to reduce financial toxicity. This study was designed to investigate the efficacy and safety of low-dose nivolumab in the management of hepatocellular carcinoma (HCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed patients with HCC who received 20 or 100\u2009mg of nivolumab intravenously every 2\u2009weeks. The objective response rate was determined in accordance with the Response Evaluation Criteria in Solid Tumors criteria version 1.1. The Cox regression model and Kaplan\u2013Meier method were used to analyze hazard factors, progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 78 patients were enrolled, including 49 with hepatitis B virus (HBV) and 23 with hepatitis C virus (HCV). All patients were staged as Barcelona Clinic Liver Cancer stage C, and 20 patients were classified as having Child\u2013Pugh classification B (7). Nivolumab 20\u2009mg was an independent prognostic factor for better PFS, and albumin-bilirubin grade 1 was the independent prognostic factor for superior OS in the multivariate analyses. Patients with better HBV (HBV DNA &lt;\u2009500\u2009IU\/ml) and HCV (HCV RNA undetectable) controls had superior OS. All AEs were grade 1\u20132 in severity, and all patients tolerated nivolumab without treatment interruption or dose adjustment. Additionally, 31 patients underwent subsequent therapy after nivolumab treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Low-dose nivolumab may be effective with manageable toxicity and can be an alternative option to reduce financial toxicity in patients with advanced HCC who cannot afford the high cost of immune checkpoint inhibitors in real-world practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10271-6","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T22:03:01Z","timestamp":1667944981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Low-dose nivolumab in advanced hepatocellular carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Yen-Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"10271_CR1","unstructured":"Report CRA. Taipei City: Health Promotion Administration, Ministry of Health and Welfare. Taiwan. 1972\u20132019;2019."},{"issue":"1","key":"10271_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54\u201363.","journal-title":"N Engl J Med"},{"issue":"10064","key":"10271_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet"},{"issue":"1","key":"10271_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"10126","key":"10271_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"4","key":"10271_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"10271_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u201396.","journal-title":"Lancet Oncol"},{"issue":"22","key":"10271_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"10271_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"20","key":"10271_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"10088","key":"10271_CR11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"7","key":"10271_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"3","key":"10271_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","volume":"71","author":"T Yau","year":"2019","unstructured":"Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543\u201352.","journal-title":"J Hepatol"},{"issue":"11","key":"10271_CR14","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6(11):e204564.","journal-title":"JAMA Oncol"},{"issue":"5","key":"10271_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hon.2787","volume":"38","author":"TSY Chan","year":"2020","unstructured":"Chan TSY, Hwang YY, Khong PL, Leung AYH, Chim CS, Tse EWC, et al. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting. Hematol Oncol. 2020;38(5):726\u201336.","journal-title":"Hematol Oncol"},{"issue":"5","key":"10271_CR16","doi-asserted-by":"publisher","first-page":"e000332","DOI":"10.1136\/esmoopen-2018-000332","volume":"3","author":"SH Yoo","year":"2018","unstructured":"Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, et al. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018;3(5):e000332.","journal-title":"ESMO Open"},{"issue":"3","key":"10271_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000512000","volume":"99","author":"JJ Zhao","year":"2021","unstructured":"Zhao JJ, Kumarakulasinghe NB, Muthu V, Lee M, Walsh R, Low JL, et al. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience. Oncology. 2021;99(3):192\u2013202.","journal-title":"Oncology"},{"key":"10271_CR18","unstructured":"FDA. Modification of the dosage regimen for nivolumab [accessed 2022 July 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/modification-dosage-regimen-nivolumab."},{"issue":"13","key":"10271_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"26","key":"10271_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"key":"10271_CR21","unstructured":"Common Terminology Criteria for Adverse Events v5.0 (CTCAE) November 27, 2017 Publication. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"2","key":"10271_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"4","key":"10271_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u201370.","journal-title":"Hepatol Int"},{"issue":"3","key":"10271_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329\u201338.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10271_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"10271_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"9","key":"10271_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10271_CR28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","volume":"28","author":"X Zhao","year":"2017","unstructured":"Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017;28(8):2002\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"10271_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000501275","volume":"8","author":"LC Lu","year":"2019","unstructured":"Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, et al. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019;8(6):480\u201390.","journal-title":"Liver Cancer"},{"issue":"3","key":"10271_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, et al. CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600\u20139.","journal-title":"J Hepatol"},{"issue":"1 Pt B","key":"10271_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.amjsurg.2022.01.008","volume":"224","author":"RY Guan","year":"2022","unstructured":"Guan RY, Sun BY, Wang ZT, Zhou C, Yang ZF, Gan W, et al. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. Am J Surg. 2022;224(1 Pt B):494\u2013500.","journal-title":"Am J Surg"},{"issue":"27","key":"10271_CR32","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.3748\/wjg.v21.i27.8249","volume":"21","author":"S Kubo","year":"2015","unstructured":"Kubo S, Takemura S, Tanaka S, Shinkawa H, Nishioka T, Nozawa A, et al. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2015;21(27):8249\u201355.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10271_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5114\/ceh.2018.78127","volume":"4","author":"M Pazgan-Simon","year":"2018","unstructured":"Pazgan-Simon M, Simon KA, Jarowicz E, Rotter K, Szymanek-Pasternak A, Zuwala-Jagiello J. Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence. Clin Exp Hepatol. 2018;4(3):210\u20136.","journal-title":"Clin Exp Hepatol"},{"issue":"13","key":"10271_CR34","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3748\/wjg.v21.i13.3860","volume":"21","author":"YQ Zhang","year":"2015","unstructured":"Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3860\u20136.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10271_CR35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312.","journal-title":"J Hepatol"},{"issue":"4","key":"10271_CR36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996\u20131005 e1001.","journal-title":"Gastroenterology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10271-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T22:05:30Z","timestamp":1667945130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10271-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10271"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10271-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (202101199B0) and conducted in accordance with the Declaration of Helsinki. The requirement for written informed consent was waived due to the retrospective design of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1153"}}